NovaQuest Capital Management acquires CutisPharma

US privately-held drugmaker CutisPharma today announced that it has been acquired by NovaQuest Capital Management.

Founded in 1998, for around two decades CutisPharma has been the industry leader in providing innovative solutions to pharmacists, with its recently approved US Food and Drug Administration-approved Firvanq (vancomycin) oral solution kit by the FDA. Upon launch it will be the only FDA-approved oral vancomycin solution treatment commercially available, improving patient access and reducing pharmacist burden by no longer having to compound oral liquid formulations.

As a part of the transaction, financial terms of which were not disclosed, Goldman Sachs Specialty Lending Group has provided financing to further support CutisPharma's growth requirements.